Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-3077 in Adults With Retinitis Pigmentosa
NCT06891885Phase 2Recruiting
- Sponsor
- Sumitomo Pharma America
- Start
- Apr 2026
- Primary completion
- Oct 2028
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of DSP-3077 in retinitis pigmentosa (RP), sponsored by Sumitomo Pharma America. Started Apr 2026; status: recruiting.
02
Drugs
DSP-3077
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT06891885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891885.